Fulcrum Therapeutics announces $75M public offering of common stock at $7.82/share

Fulcrum Therapeutics, Inc.

9,590,792 shares offered at $7.82/share; gross proceeds $75 million.
Net proceeds estimated at $70.3 million ($80.9 million if underwriters exercise full 30-day option for 1,438,618 additional shares).
Goldman Sachs & Co. and SVB Securities act as lead joint book-running managers; closing expected on August 18, 2022.
Company subject to 60-day lock-up; directors and executive officers subject to 30-day lock-up.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.